Protocols

Mylan, Amgen score unanimous AdComm backing for Roche copycats; Alder raises $161M

Mylan and Amgen breezed through their advisory committee reviews on Thursday without any unexpected kickbacks for their two new knockoffs of a pair of Roche megablockbusters. Both won nods in unanimous votes, which is what you’d expect for drugs given a clean assessment by FDA insiders. Mylan was up with MYL-1401O, a biosimilar of Herceptin. Amgen, meanwhile, won applause for its copycat of Avastin.

CS Bio wants to build a new HQ building on the bayfront in Menlo Park, CA, according to a report in the San Jose Mercury News. The company says it plans to triple its work force in the next five years to about 300.

Alder BioPharmaceuticals $ALDR has raised $161 million as it preps for a BLA on its CGRP migraine therapy. The Bothell, WA-based biotech is building a commercial organization for their drug, which looks like it will compete against a range of rivals in the field.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->